Different Hemostatic Agents Used in Partial Pulpotomy on Pulp Survival and Postoperative Pain

Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age15-55
SponsorCukurova University

About this trial

This randomized clinical trial evaluates the efficacy of sodium hypochlorite (NaOCl), chlorhexidine (CHX), and cold saline as hemostatic agents in partial pulpotomy. The study compares postoperative pain (via VAS scores) and pulp survival (via clinical/radiographic evaluation) at 1, 3, 7 days, 6 months, and 12 months

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

Permanent teeth with carious pulp exposure (no spontaneous pain).

Positive vitality test (Endo-Ice).

No periapical radiolucency.

Disqualifiers

Systemic diseases affecting healing.

Pregnancy.

Non-vital pulp/necrosis

Trial design

Design model

Parallel

Treatments tested in this trial

  • Sodium Hypochlorite 2,5%

    Drug

    2.5% NaOCl applied for 1 min to exposed pulp for hemostasis, followed by standard pulp capping

  • Chlorhexidine

    Drug

    2% CHX applied for 1 min to achieve hemostasis, with identical subsequent steps to NaOCl group

  • Cold Saline

    Drug

    Hemostasis via 4°C saline (1 Min), then standardized pulp capping

Treatment groups

75 Participants
are divided into 3 treatment groups
Group A: Arm 1Experimental treatment 1 intervention
Group B: Arm 2Experimental treatment 1 intervention
Group C: Arm 3Experimental treatment 1 intervention

Trial outcomes

Primary outcomes

1

Postoperative Pain

The patient will be asked to rate the pain on the 1st, 3rd and 7th day according to VAS. (The patient is asked to score their pain in this range, with 0 being the lowest and 10 being the highest.)

Time frame
1 week
2

Pulp Survival Rate

The pulp is expected to be vital, without percussion tenderness and without spontaneous pain

Time frame
12 months

Secondary outcomes

1

Clinical Success

Maintaining the integrity of the restoration No need for endodontics treatments

Time frame
12 months

Other outcomes

Sponsors and contacts

Click on the lead sponsor to view all of their trials.